Program
solriamfetol
Also written as “JZP-110”, “Solriamfetol” and “Solriamfetol 300 mg”.
Its studies are mostly in Narcolepsy · Attention Deficit Disorder with Hyperactivity · Sleep Apnea, Obstructive · Depressive Disorder, Major · Disorders of Excessive Somnolence, led by 4 companies.
Drug pageSolriamfetol: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Axsome Therapeuticsits history only | 117 open or running | phase 4since Feb 25, 2021 | Feb 25, 2021 | Dec 2026phase 3 · NCT06413433 |
| Jazz Pharmaceuticalsits history only | 90 open or running | phase 3since Jan 15, 2015 | Dec 2, 2011 | none ahead |
| Ignis Therapeutics (Suzhou)its history only | 10 open or running | phase 3since Sep 27, 2023 | Sep 27, 2023 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 2since Nov 17, 2003 | Nov 17, 2003 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 17, 2003.
- Jan 15, 20154 phase 3 studiesJazz Pharmaceuticals · NCT02348632, NCT02348619, NCT02348606 and 1 more
- Jun 10, 20162 phase 2 studiesJazz Pharmaceuticals · NCT02806908, NCT02806895
- Dec 9, 2016Named solriamfetolINNProposed as its International Nonproprietary Name in WHO's List 116 · before, JZP-110
- Jan 23, 2017Phase 2 study in Disorders of Excessive SomnolenceJazz Pharmaceuticals · NCT03037203 · 66 enrolled · United States
- Feb 25, 2021Axsome Therapeutics’ first study: phase 4 study in Disorders of Excessive SomnolenceNew to Axsome TherapeuticsAxsome Therapeutics · NCT04789174 · 59 enrolled · United States, Canada, Italy and more
- Aug 10, 2021Phase 1 study in NarcolepsyAxsome Therapeutics · NCT05008341 · 6 enrolled · United States
- Jul 25, 2023Phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT05972044 · 516 enrolled · United States
- Sep 27, 2023Ignis Therapeutics (Suzhou)’s first study: phase 3 study in Sleep Apnea, ObstructiveNew to Ignis Therapeutics (Suzhou)Ignis Therapeutics (Suzhou) · NCT06103825 · 204 enrolled · China
- Apr 8, 2024Phase 3 study in Depressive Disorder, MajorAxsome Therapeutics · NCT06360419 · 346 enrolled · United States
- May 9, 2024Phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06413433 · 450 planned · United States
- Aug 21, 2024Phase 3 study in Disorders of Excessive SomnolenceAxsome Therapeutics · NCT06568367 · 520 planned · United States, Canada
- Mar 14, 2025Phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06878976 · 236 planned · United States
- Mar 16, 2026Phase 3 study in Depressive Disorder, MajorAxsome Therapeutics · NCT07484217 · 508 planned · United States
- Jul 16, 20262 phase 3 studies in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07717892, NCT07717879
- Aug 14, 2026Phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07773883 · 300 planned · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Disorders of Excessive SomnolenceAxsome Therapeutics · NCT06568367
- Dec 2026Primary completion: phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06413433
- Dec 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07773883
- Dec 2027Primary completion: phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06878976
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07773883Attention Deficit Disorder with Hyperactivity · United States | 3 | By invitation | Axsome Therapeutics | Dec 2027 | 300 |
| NCT07717892Attention Deficit Disorder with Hyperactivity · United States | 3 | Recruiting | Axsome Therapeutics | Jun 30, 2028 | 468 |
| NCT07717879Attention Deficit Disorder with Hyperactivity · United States | 3 | Recruiting | Axsome Therapeutics | Jun 30, 2028 | 468 |
| NCT07484217Depressive Disorder, Major · United States | 3 | Recruiting | Axsome Therapeutics | Dec 2028 | 508 |
| NCT06878976Binge-Eating Disorder · United States | 3 | By invitation | Axsome Therapeutics | Dec 2027 | 236 |
| NCT06568367Disorders of Excessive Somnolence · United States, Canada | 3 | Recruiting | Axsome Therapeutics | Dec 2026 | 520 |
| NCT06413433Binge-Eating Disorder · United States | 3 | Recruiting | Axsome Therapeutics | Dec 2026 | 450 |
| NCT06360419Depressive Disorder, Major · United States | 3 | Completed | Axsome Therapeutics | Dec 31, 2024 | 346 |
| NCT06103825Sleep Apnea, Obstructive · China | 3 | Completed | Ignis Therapeutics (Suzhou) | Jul 20, 2024 | 204 |
| NCT05972044Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Axsome Therapeutics | Feb 7, 2025 | 516 |
| NCT05008341Narcolepsy · United States | 1 | Completed | Axsome Therapeutics | Apr 15, 2022 | 6 |
| NCT04789174Disorders of Excessive Somnolence · United States, Canada, Italy and more | 4 | Completed | Axsome Therapeutics | Sep 19, 2022 | 59 |
| NCT03037203Disorders of Excessive Somnolence · United States | 2 | Completed | Jazz Pharmaceuticals | Aug 2018 | 66 |
| NCT02806908Narcolepsy · Netherlands | 2 | Completed | Jazz Pharmaceuticals | May 19, 2019 | 24 |
| NCT02806895Sleep Apnea, Obstructive · Netherlands | 2 | Completed | Jazz Pharmaceuticals | May 28, 2019 | 34 |
| NCT02348632Narcolepsy · United States, Canada, Finland and more | 3 | Completed | Jazz Pharmaceuticals | Dec 2017 | 645 |
| NCT02348619Sleep Apnea, Obstructive · United States, Finland, France and more | 3 | Completed | Jazz Pharmaceuticals | Nov 2016 | 174 |
| NCT02348606Sleep Apnea, Obstructive · United States, Canada, France and more | 3 | Completed | Jazz Pharmaceuticals | Dec 2016 | 476 |
| NCT02348593Narcolepsy · United States, Canada, Finland and more | 3 | Completed | Jazz Pharmaceuticals | Feb 2017 | 239 |
| NCT01681121Narcolepsy · United States | 2 | Completed | Jazz Pharmaceuticals | Aug 2013 | 93 |
| NCT01485770Narcolepsy · United States | 2 | Completed | Jazz Pharmaceuticals | May 2012 | 33 |
| NCT00073203Depressive Disorder, Major · United States | 2 | Completed | Johnson & Johnson | 488 |
How it is read
Names in the registry
- “JZP-110”, 7 entries
- “Solriamfetol”, 4 entries
- “Solriamfetol 300 mg”, 4 entries
- “Solriamfetol 150 mg”, 3 entries
- “Solriamfetol Dose A”, 2 entries
Conditions, from the studies’ own filings
- Narcolepsy, 6 studies
- Attention Deficit Disorder with Hyperactivity, 4 studies
- Sleep Apnea, Obstructive, 4 studies
- Depressive Disorder, Major, 3 studies
- Disorders of Excessive Somnolence, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.